Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
04 05 2021
Historique:
received: 12 02 2021
accepted: 21 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 22 6 2021
Statut: epublish

Résumé

The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS. We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks' gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit. The 40 women had a mean age of 30.5 ± 4.6 years at their first episode of preeclampsia; 21 were nulligravid (52.5%), 12 (30%) had already been diagnosed with APS, and 21 (52.5%) had a triple-positive antiphospholipid (aPL) antibody test. Preeclampsia occurred at a median gestational age of 25.5 weeks (IQR 23-29). It was associated with HELLP in 18 cases (45%), eclampsia in 6 (15%), placental abruption in 3 (7.5%), catastrophic APS in 3 (7.5%), and foetal and neonatal death in 11 and 15 cases. Overall, 14 (35%) children survived, born at a median gestational age of 31 weeks. Among other APS criteria, 16 women (40%) experienced at least one thrombosis, 17 (42.5%) an intrauterine foetal death, and 19 (47.5%) at least one episode of HELLP during follow-up (median 5 years, IQR = 2-8). None had three or more consecutive miscarriages. Notably, 12 women (30%) had systemic lupus erythematosus. Severe preeclampsia led to high mortality in the offspring. Almost half of these women experienced other APS features, but not three consecutive miscarriages.

Sections du résumé

BACKGROUND
The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS.
METHODS
We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks' gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit.
RESULTS
The 40 women had a mean age of 30.5 ± 4.6 years at their first episode of preeclampsia; 21 were nulligravid (52.5%), 12 (30%) had already been diagnosed with APS, and 21 (52.5%) had a triple-positive antiphospholipid (aPL) antibody test. Preeclampsia occurred at a median gestational age of 25.5 weeks (IQR 23-29). It was associated with HELLP in 18 cases (45%), eclampsia in 6 (15%), placental abruption in 3 (7.5%), catastrophic APS in 3 (7.5%), and foetal and neonatal death in 11 and 15 cases. Overall, 14 (35%) children survived, born at a median gestational age of 31 weeks. Among other APS criteria, 16 women (40%) experienced at least one thrombosis, 17 (42.5%) an intrauterine foetal death, and 19 (47.5%) at least one episode of HELLP during follow-up (median 5 years, IQR = 2-8). None had three or more consecutive miscarriages. Notably, 12 women (30%) had systemic lupus erythematosus.
CONCLUSIONS
Severe preeclampsia led to high mortality in the offspring. Almost half of these women experienced other APS features, but not three consecutive miscarriages.

Identifiants

pubmed: 33947469
doi: 10.1186/s13075-021-02518-7
pii: 10.1186/s13075-021-02518-7
pmc: PMC8094564
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

134

Références

Lupus. 2020 Nov;29(13):1736-1742
pubmed: 32838621
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Lupus. 2018 Oct;27(12):1903-1910
pubmed: 30028257
Obstet Gynecol. 2002 Jan;99(1):159-67
pubmed: 16175681
Curr Opin Obstet Gynecol. 2017 Dec;29(6):397-403
pubmed: 28915160
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Ann Intern Med. 2015 Aug 4;163(3):153-63
pubmed: 26098843
Ann Rheum Dis. 2005 Feb;64(2):273-8
pubmed: 15647435
Arthritis Res Ther. 2018 Nov 06;20(1):249
pubmed: 30400982
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Semin Thromb Hemost. 2014 Mar;40(2):163-71
pubmed: 24500573
Ann Rheum Dis. 2017 Mar;76(3):476-485
pubmed: 27457513
Lupus. 2010 Jan;19(1):58-64
pubmed: 19897518
Lupus. 2020 Aug;29(9):1050-1059
pubmed: 32536318
Ann Rheum Dis. 2015 Jun;74(6):1011-8
pubmed: 24464962

Auteurs

Maddalena Larosa (M)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.

Véronique Le Guern (V)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Nathalie Morel (N)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Mériem Belhocine (M)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
Sacré-Coeur Hospital, Internal Medicine Department, University of Montréal, Montréal, Canada.

Amelia Ruffatti (A)

Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.

Nicolas Martin Silva (NM)

University Hospital Center of Caen, Department of Internal Medicine, Caen, France.

Romain Paule (R)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Luc Mouthon (L)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
Université de Paris, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.

Michel Dreyfus (M)

University Hospital Center of Caen, Gynecology and Obstetrics Department, Caen, France.

Jean-Charles Piette (JC)

AP-HP, Pitié-Salpétrière University Hospital, Internal Medicine and Clinical Immunology Department, Centre de référence maladies auto-immunes et systémiques rares de l'Ile de France, Paris, France.

Odile Souchaud-Debouverie (O)

Poitiers University Hospital, Department of Medicine, Internal Medicine Department, Paris, France.

Catherine Deneux-Tharaux (C)

INSERM U 1153, Obstetrical, Perinatal and Paediatric Epidemiology (EPOPé research team), DHU Risks in Pregnancy, Université de Paris, Paris, France.

Gaelle Guettrot-Imbert (G)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Vassilis Tsatsaris (V)

AP-HP, Cochin Broca Hôtel-Dieu Hospital, Port-Royal maternity, DHU Risk in Pregnancy, INSERM Unité 1139, Paris, France.

Emmanuelle Pannier-Metzger (E)

AP-HP, Cochin Broca Hôtel-Dieu Hospital, Port-Royal maternity, DHU Risk in Pregnancy, INSERM Unité 1139, Paris, France.

Anne Murarasu (A)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.

Andrea Doria (A)

Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.

Nathalie Costedoat-Chalumeau (N)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France. nathalie.costedoat@gmail.com.
Université de Paris, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France. nathalie.costedoat@gmail.com.
INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. nathalie.costedoat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH